Top

Published in:

Open Access 01-12-2015 | Research

Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation

Authors: Daniela Melis, Alessandro Rossi, Rosario Pivonello, Mariacarolina Salerno, Francesca Balivo, Simona Spadarella, Giovanna Muscogiuri, Roberto Della Casa, Pietro Formisano, Generoso Andria, Annamaria Colao, Giancarlo Parenti

Published in: Orphanet Journal of Rare Diseases | Issue 1/2015

Abstract

Background

In GSDIa, glucose 6-phosphate (G6P) accumulates in the endoplasmic reticulum (ER); in GSDIb, G6P levels are reduced in ER. G6P availability directly modulates the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), an ER-bound enzyme playing a key role in the development of the metabolic syndrome (MS).

Objective

To evaluate the prevalence of MS and Insulin Resistance (IR) in GSDIa and GSDIb patients.

Patients and Methods

This was a prospective study. All the enrolled patients were followed at the Department of Pediatrics “Federico II” University of Naples for 10 years. Clinical and biochemical parameters of MS and the presence of IR were recorded. The results were correlated with the biochemical parameters of GSDI-related metabolic control. 10 GSDIa patient (median age 12.10 ± 1.50), 7 GSDIb patients (median age 14.90 ± 2.20 were enrolled in the study. They were compared to 20 and 14 age and sex matched controls, respectively. 10 GSDIa patients (median age 24.60 ± 1.50) and 6 GSDIb patients (median age 25.10 ± 2.00) completed the 10-year-follow-up. At the end of the study the patients’ data were compared to 10 and 6 age and sex matched controls, respectively.

Results

At study entry, 20 % GSDIa patients had MS and 80 % showed 2 criteria for MS. GSDIa patients showed higher HOMA-IR than controls and GSDIb patients (p < 0.001, p < 0.05), respectively. Baseline ISI was lower in GSDIa than controls (p < 0.001). QUICKI was significantly lower in GSDIa than in controls (p < 0.001). At the end of the study 70 % of GSDIa patients had MS and 30 % showed 2 criteria for MS. HOMA-IR was higher in GSDIa than controls (p < 0.01). Baseline ISI was higher in GSDIb than controls (p < 0.005) and GSD1a (p < 0.05). QUICKI was lower in GSD1a patients than in controls (p < 0.03). VAI was higher in GSDIa patients than controls (p < 0.001) and GSDIb patients (p = 0.002).

Conclusions

Our data showed high prevalence of IR and MS in GSDIa patients. We speculate a possible role of 11βHSD1 modulation by G6P availability. We suggest a routine metabolic assessment in GSDIa patients.

Czegle I, Csala M, Mandl J, Benedetti A, Karádi I, Bánhegyi G. G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome. World J Hepatol. 2012;4:129–38.PubMedCentralPubMedCrossRef

Wake DJ, Walker BR. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol Cell Endocrinol. 2004;215:45–54.PubMedCrossRef

Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294(5549):2166–70.PubMedCrossRef

Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, et al. Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A. 2004;101(18):7088–93.PubMedCentralPubMedCrossRef

Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A. 1997;94:14924–9.PubMedCentralPubMedCrossRef

Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med. 2005;202:517–27.PubMedCentralPubMedCrossRef

Wang SJ, Birtles S, de Schoolmeester J, Swales J, Moody G, Hislop D, et al. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice. Diabetologia. 2006;49:1333–7.PubMedCrossRef

Schnackenberg CG, Costell MH, Krosky DJ, Cui J, Wu CW, Hong VS, et al. Chronic inhibition of 11 β -hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome. Biomed Res Int. 2013;2013:427640.PubMedCentralPubMedCrossRef

Gathercole LL, Lavery GG, Morgan SA, Cooper MS, Sinclair AJ, Tomlinson JW, et al. 11β-Hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev. 2013;34:525–55.PubMedCrossRef

10.

Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology. 2001;142(4):1371–6.PubMed

11.

Du H, Liu L, Wang Y, Nakagawa Y, Lyzlov A, Lutfy K, et al. Specific reduction of G6PT may contribute to downregulation of hepatic 11β-HSD1 in diabetic mice. J Mol Endocrinol. 2013;50(2):167–78.PubMedCentralPubMedCrossRef

12.

Chou JY, Matern D, Mansfield BC, Chen YT. Type I Glycogen Storage Disease: disorders of the glucose-6-phosphatase complex. Curr Mol Med. 2002;2:121–43.PubMedCrossRef

13.

Hutton JC, O’Brien RM. Glucose-6-phosphatase catalytic subunit gene family. J Biol Chem. 2009;284:29241–5.PubMedCentralPubMedCrossRef

14.

Bali DS, Chen YT, Goldstein JL. Glycogen Storage Disease Type I. 2006 [Updated 2013]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2013.

15.

Melis D, Parenti G, Gatti R, Casa RD, Parini R, Riva E, et al. Efficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study. Clin Endocrinol (Oxf). 2005;63:19–25.2.CrossRef

16.

Melis D, Della Casa R, Parini R, Rigoldi M, Cacciapuoti C, Marcolongo P, et al. Vitamin E supplementation improves neutropenia and reduces the frequency of infections in patients with glycogen storage disease type 1b. Eur J Pediatr. 2009;168:1069–74.PubMedCrossRef

17.

Walker EA, Ahmed A, Lavery GG, Tomlinson JW, Kim SY, Cooper MS, et al. 11beta-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function. J Biol Chem. 2007;282:27030–6.PubMedCrossRef

18.

Borai A, Livingstone C, Kaddam I, Ferns G. Selection of the appropriate method for the assessment of insulin resistance. BMC Med Res Methodol. 2011;11:158.PubMedCentralPubMedCrossRef

19.

Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15–26.PubMedCrossRef

20.

Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.PubMedCrossRef

21.

Amato MC, Giordano C. Visceral adiposity index: an indicator of adipose tissue dysfunction. Int J Endocrinol. 2014;2014:730827.PubMedCentralPubMed

22.

Friedrich N, Thuesen B, Jørgensen P, Juul A, Spielhagen C, Wallaschofski H, et al. The Association Between IGF-I and Insulin Resistance A general population study in Danish adults. Diab Care. 2012;35:768–73. doi:10.2337/dc11-1833. Epub 2012 Feb 28.CrossRef

23.

Amato MC, Giordano C, Pitrone M, Galluzzo A. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011;10:183.PubMedCentralPubMedCrossRef

24.

Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease type I (ESGSDI). Eur J Ped. 2002;161:S20–34.CrossRef

25.

Melis D, Pivonello R, Cozzolino M, Della Casa R, Balivo F, Del Puente A, et al. Impaired bone metabolism in glycogen storage disease type 1 is associated with poor metabolic control in GSD1a and with Granulocyte Colony Stimulating Factor therapy in GSD1b. Horm Res Paediatr. 2014;81(1):55–62.PubMedCrossRef

26.

Bánhegyi G, Csala M, Benedetti A. Hexose-6-phosphate dehydrogenase: linking endocrinology and metabolism in the endoplasmic reticulum. J Mol Endocrinol. 2009;42(4):283–9.PubMedCrossRef

27.

Marcolongo P, Fulceri R, Gamberucci A, Czegle I, Banhegyi G, Benedetti A. Multiple roles of glucose-6-phosphatases in pathophysiology: state of the art and future trends. Biochim Biophys Acta. 2013;1830:2608–18.PubMedCrossRef

28.

Pivonello R, De Leo M, Vitale P, Cozzolino A, Simeoli C, De Martino MC, et al. Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology. 2010;92 Suppl 1:77–81.PubMedCrossRef

Title: Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation
Authors: Daniela Melis
Alessandro Rossi
Rosario Pivonello
Mariacarolina Salerno
Francesca Balivo
Simona Spadarella
Giovanna Muscogiuri
Roberto Della Casa
Pietro Formisano
Generoso Andria
Annamaria Colao
Giancarlo Parenti
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2015
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-015-0301-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation

Abstract

Background

Objective

Patients and Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Patients and Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Drug repositioning can accelerate discovery of pharmacological chaperones

Behavioral disturbance and treatment strategies in Smith-Magenis syndrome

Prevalence of inherited neurotransmitter disorders in patients with movement disorders and epilepsy: a retrospective cohort study

Expanding the clinical spectrum of hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis due to FAM111B mutations

Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries

Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act